Circulating RNA signatures report age-related disease biology
PrimaryTAmiRNA's diagnostic theory is that disease and aging-related tissue states alter the abundance of cell-free RNAs, including microRNAs, mRNAs, and long non-coding RNAs, in blood or other liquid-biopsy samples. Measuring these RNA signatures and integrating them with computational analysis should therefore reveal otherwise inaccessible biology in conditions such as senescence-associated disease, liver dysfunction, cardiovascular disease, diabetes, oncology, and musculoskeletal disorders. Testable predictions are that specific circulating RNA panels will distinguish affected from control individuals, correlate with clinical severity or disease duration, and predict outcomes or treatment response better than non-molecular clinical measures alone.
Popperian evaluation
The core premise is credible: damaged, diseased, treated, or stressed tissues can change circulating RNA abundance, and blood-based miRNA measurement is technically practical. The theory gets weaker when it implies broad biological specificity across senescence, liver disease, cardiovascular disease, diabetes, oncology, and musculoskeletal disorders. Circulating RNA is a messy signal. Handling, extracellular-vesicle isolation, treatment exposure, comorbid disease, and cell source ambiguity can all move the readout.
Supporting evidence: Rotator cuff repair patients had longitudinal plasma miRNA differences after zoledronic acid treatment, with links to inflammation, fibrosis, collagen synthesis, vascularization, and tendon-to-bone healing biology.; Adolescents with long-duration type 1 diabetes had circulating miRNA candidates evaluated in a case-control design, supporting the idea that blood miRNAs can reflect diabetes-associated biology.; Extracellular-vesicle studies show RNA cargo can carry molecular fingerprints associated with anti-inflammatory and anti-fibrotic activity.
Counter evidence: Culture conditions and isolation methods changed extracellular-vesicle miRNA cargo, so the measured signal can reflect workflow conditions as well as biology.; The theory depends on disease-specific signal being stronger than noise from sample handling, comorbidities, treatments, and extracellular-vesicle production conditions.
The theory explains why multiple diseases show altered circulating RNA panels, especially when the same samples also differ by repair state, malignancy grade, or treatment response. But the evidence does not yet prove that the RNA signatures report otherwise inaccessible tissue biology better than simpler explanations. Inflammation, tissue injury, medication exposure, blood-cell composition, and sample processing could produce many of the same changes. The theory is plausible, but it has not beaten the obvious confounders cleanly.
Supporting evidence: Zoledronic acid treatment in rotator cuff repair produced distinct plasma miRNA profiles after surgery, while baseline levels did not differ between groups.; High-grade glioma evidence linked miR-216b abundance to malignancy grade, tumor-suppressive cell-cycle regulation, and CDK4/6 inhibitor sensitivity.; The diabetes case-control evidence supports disease-associated circulating miRNA differences in a non-oncology setting.
Counter evidence: The extracellular-vesicle evidence shows protocol-dependent miRNA changes, which gives a strong alternative explanation for some circulating RNA differences.; The outcome-prediction claim has low-confidence support in the provided evidence.; Pathway mapping from RNA panels can be biologically suggestive without proving tissue origin or causal mechanism.
This is testable. The theory predicts that predefined circulating RNA panels will separate affected cases from matched controls, track severity or disease duration, and predict outcomes or treatment response better than clinical measures alone. Those claims can fail in blinded validation cohorts, longitudinal sampling, external sites, and head-to-head models against age, sex, medication, diagnosis, imaging, and routine lab data.
Supporting evidence: The theory names measurable analytes: microRNAs, mRNAs, long non-coding RNAs, and extracellular-vesicle RNA cargo.; The proposed tests include case-control separation, longitudinal correlation with severity or duration, and prediction of outcomes or treatment response.; Sequencing and RT-qPCR make the biomarkers measurable with existing laboratory methods.
Counter evidence: The theory is broad enough that one failed disease area would not falsify the whole platform claim.; If panels are repeatedly reselected after seeing the data, the claim becomes much harder to disprove.
Reasoning tree
Public endorsements
The record does not show Alexandra Wagner endorsing, mentioning, or disputing this theory. The only evidence provided is a patent on cell-free RNA cancer biomarkers, and it lists an inventor named Josiah Wagner, not Alexandra Wagner. With no quotes, publications, or attributed public statements from Alexandra Wagner, silence is the defensible call.
The public record ties Andreas Diendorfer to multiple papers that treat circulating or extracellular miRNA patterns as disease-relevant readouts. These publications profile serum miRNAs in T1D-induced bone loss, plasma miRNAs in glioma-associated thrombosis, extracellular-vesicle miRNA signatures from endothelial cells, and plasma microRNA-transcriptomics in an aging-related vascular niche. That is active support for the core claim that cell-free RNA signatures can report underlying disease or aging biology, even if one paper also states reproducibility is still a problem.
Evidence publication IDs: 2ab26234-032c-4923-826a-199380317f3f, e03e65cf-cb8a-49fc-bfba-d7cb05c19f7c, 265e2ce9-1c3b-45c5-b0af-c159256ca213, b7b000e8-98c7-442f-ba29-6b4eb8583ce6
The only public evidence here is a 2026 publication on macrophage metabolism and extracellular vesicle cargo, including miRNAs, in bone repair. It studies how metabolic changes alter EV content and regenerative effects, but it does not discuss circulating cell-free RNA signatures as liquid-biopsy diagnostics for aging or disease states, nor does it endorse that diagnostic theory.
Evidence publication IDs: 3551fb84-3100-426f-aceb-8789c1b1ac46
There is no public evidence here. The dossier includes no quotes, records, or publications linking D Tiina Berg to this theory, so we cannot claim endorsement, mention, or contradiction.